顺尔宁治疗儿童肺炎支原体肺炎的效果及对患儿肺功能的影响探讨

Effect of Shunerning on Mycoplasma pneumoniae pneumonia in children and its influence on pulmonary function of children

目的探讨孟鲁司特钠(商品名:顺尔宁)治疗儿童肺炎支原体肺炎的效果及对患儿肺功能的影响。方法126例肺炎支原体肺炎患儿,采用随机数字表法分为实验组和对照组,各63例。对照组给予乳酸红霉素及阿奇霉素治疗,实验组在对照组基础上口服顺尔宁治疗。比较两组临床疗效、治疗前后的肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气峰值流速(PEF)、用力呼气流量(FEF)25、FEF50、FEF75]、临床症状改善时间。结果实验组治疗总有效率80.95%高于对照组的60.32%,差异有统计学意义(P<0.05)。治疗后,两组FVC、FEV1、PEF、FEF25、FEF50、FEF75均高于治疗前,差异有统计学意义(P<0.05)。治疗后,两组FVC、FEV1、PEF组间比较,差异无统计学意义(P>0.05)。治疗后,实验组FEF25(3.74±0.75)L/s、FEF50(3.31±0.71)L/s、FEF75(2.99±0.71)L/s高于对照组的(2.88±0.81)、(2.38±0.73)、(2.27±0.39)L/s,差异有统计学意义(P<0.05)。实验组喘息、咳嗽、免疫球蛋白E(IgE)高改善时间分别为(3.25±0.57)、(7.24±1.75)、(5.21±1.05)d,均短于对照组的(6.75±2.27)、(15.36±5.31)、(9.37±3.49)d,差异有统计学意义(P<0.05)。结论顺尔宁治疗肺炎支原体肺炎患儿的疗效显著,可改善患儿肺功能并缩短症状改善时间,让患儿尽早治愈出院,值得应用。

Objective To discuss the effect of montelukast sodium(trade name:Shunerning)on Mycoplasma pneumoniae pneumonia in children and its influence on pulmonary function of children.Methods A total of 126 children with Mycoplasma pneumoniae pneumonia were divided into experimental group and control group according to the random numerical table,with 63 cases in each group.The control group was treated with erythromycin lactobionate and azithromycin,and the experimental group was treated with Shunerning on the basis of the control group.Both groups were compared in terms of clinical efficacy,pulmonary function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),peak expiratory flow rate(PEF),forced expiratory flow at 25%of forced vital capacity(FEF25),forced expiratory flow at 50%of forced vital capacity(FEF50),forced expiratory flow at 75%of forced vital capacity(FEF75)]before and after treatment,and the improvement time of clinical symptoms.Results The total effective rate of 80.95%in the experimental group was higher than that of 60.32%in the control group,and the difference was statistically significant(P<0.05).After treatment,FVC,FEV1,PEF,FEF25,FEF50 and FEF75 in both groups were higher than those before treatment in this group,and the difference was statistically significant(P<0.05).After treatment,there was no statistically significant difference in FVC,FEV1 and PEF between the two groups(P>0.05).After treatment,the experimental group had FEF25 of(3.74±0.75)L/s,FEF50 of(3.31±0.71)L/s,and FEF75 of(2.99±0.71)L/s,which were higher than those of(2.88±0.81),(2.38±0.73),and(2.27±0.39)L/s in the control group,and the differences were statistically significant(P<0.05).The improvement time of wheezing,cough and immunoglobulin E(IgE)in the experimental group were(3.25±0.57),(7.24±1.75)and(5.21±1.05)d,which were shorter than those of(6.75±2.27),(15.36±5.31)and(9.37±3.49)d in the control group,and the differences were statistically significant(P<0.05).Conclusion Shunerning is effective in the treatment of children with Mycoplasma pneumoniae pneumonia,and it can improve the pulmonary function and shorten the time of symptom improvement,so that children can be cured and discharged as soon as possible,which is worthy of application.